Get MoonLake Immunotherapeutics alerts:MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) – Wedbush issued their Q2 2026 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Monday, September 29th. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics’ FY2029 earnings at $3.60 EPS. Read Our Latest Stock Report on MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics Stock Down 1.5%MLTX opened at $7.06 on Wednesday. See AlsoReceive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.